The argenx Unnatural Products deal buys a macrocyclic peptide discovery platform and its Santa Cruz research team. It also brings a portfolio of therapeutic macrocycles, none of which the companies have named. argenx will pay $550 million upfront in cash. Up to $595 million more depends on development and regulatory milestones. The two companies announced the agreement on 9 November 2026. It had not closed as at 11 November 2026, and closing is expected by the end of 2026.
How Much Is argenx Paying for Unnatural Products?
In its announcement of the acquisition, argenx described “an upfront payment of $550 million in cash on hand”. A further sum of up to $595 million is “contingent on achievement of specified development and regulatory milestones”. argenx puts the total potential value at up to approximately $1.15 billion. That total is not the price paid. The upfront sum is the only fixed payment the release describes.
Unnatural Products (UNP) described the contingent element differently. UNP’s own release refers to “$550 million upfront plus contingent value rights tied to development and regulatory milestones”. Neither release states when any milestone could fall due. Neither names the programmes that would trigger them.
argenx already held a minority stake in UNP before the deal. It will now buy all the remaining shares. Neither release disclosed the size of that stake, as at a search on 11 November 2026. Both boards have approved the transaction, according to argenx. Morgan Stanley & Co. LLC is argenx’s exclusive financial adviser, and DLA Piper LLP its legal adviser. Latham & Watkins LLP is legal counsel to UNP. argenx flagged its announcement as inside information under the EU Market Abuse Regulation.
argenx Unnatural Products Deal Terms at a Glance
| Item | Detail |
|---|---|
| Buyer | argenx SE (Euronext and Nasdaq: ARGX) |
| Target | Unnatural Products, Inc. (UNP), private, Santa Cruz, California |
| Structure | Purchase of all remaining shares; argenx already holds a minority stake |
| Upfront | $550 million in cash on hand |
| Contingent payments | Up to $595 million on development and regulatory milestones (described by UNP as contingent value rights) |
| Total potential value | Up to approximately $1.15 billion (argenx release) |
| Royalties | Not described in either release |
| Expected close | By the end of 2026 |
| Conditions | Customary closing conditions |
| Status at 11 November 2026 | Signed, not completed |
| Advisers | argenx: Morgan Stanley & Co. LLC (financial), DLA Piper LLP (legal). UNP: Latham & Watkins LLP (legal) |
What the argenx Unnatural Products Deal Brings: A Peptide Platform
UNP designs macrocyclic peptides, which are ring-shaped peptide molecules. BioPharma Dive describes them as larger and more complex than typical small molecules, yet small enough to be swallowed. UNP says its platform combines AI-guided design, massively parallel synthesis and direct-to-biology screening. The company says the aim is to reach hard-to-drug targets, including intracellular ones.
argenx says the platform could support “oral and long-acting medicines” for immune-mediated diseases. Its existing business was built on antibody engineering. Karen Massey is Chief Executive Officer of argenx. She said UNP “adds macrocyclic peptide capabilities that are highly complementary to our antibody engineering”.
However, neither release names a UNP programme, target or development stage. Neither describes a UNP molecule in clinical trials. In March 2026, UNP said it aimed to advance its lead programmes “toward the clinic”. Its programmes then spanned cardiometabolic, inflammatory and immunological diseases, according to that release.
The people are part of the purchase too. UNP will keep its team and leadership in Santa Cruz, and the company has more than 50 employees. The site will serve as “argenx’s home for peptide discovery”, according to argenx. UNP will lead discovery work within a framework agreed with argenx. argenx, meanwhile, will handle clinical development and commercialisation.
What Happens to UNP’s Other Partnerships?
UNP lists partnerships with Novartis, Merck and BridgeBio alongside argenx. In February 2026, UNP announced a Novartis licence for a cardiovascular programme. That deal offered up to $100 million in upfront and pre-IND milestone payments. It also carried up to $1.7 billion in development, regulatory and commercial milestones. UNP is eligible for tiered royalties from mid-single digits up to low double digits on net sales. The argenx Unnatural Products deal releases do not say whether these partnerships continue after closing. That question remained open as at 11 November 2026.
Why Are argenx and UNP Doing the Deal?
argenx frames the purchase within its immunology ambitions. Massey said: “Our ambition is to be the leading immunology innovation company”. She also pointed to the existing relationship. She noted the companies had worked together “for more than two years”. As a result, “we also know there is a strong fit in how we work”, she added.
That relationship began with a multi-target collaboration announced on 1 July 2025. Under it, argenx identified targets and held an exclusive option to develop and commercialise products. UNP received a double-digit-million-dollar upfront payment. It was also eligible for milestone and option payments of up to approximately $1.5 billion. Tiered royalties on net sales completed the package. argenx agreed to make an equity investment at that time. It then joined UNP’s $45 million Series B, announced on 16 March 2026.
UNP’s founders welcomed the sale. Cameron Pye, CEO and Co-Founder of UNP, said: “I am so proud of what our team has accomplished.” Pye co-founded the company in 2016 with Joshua Schwochert, now its Chief Scientific Officer. Schwochert called the deal “the result of years of scientific innovation and tenacious execution by an extraordinary team.”
When Will the argenx Unnatural Products Deal Close?
argenx said: “The acquisition is expected to close by the end of the year, subject to customary closing conditions.” Neither release lists specific antitrust filings or a shareholder vote. Still, argenx’s forward-looking statements cite the risk of failing to obtain required regulatory approvals. Until closing, UNP remains a separate company in which argenx holds a minority stake.
argenx will fund the upfront payment from cash on hand. It reported cash, cash equivalents and current financial assets of $3.7 billion at 30 September 2026. That figure appeared in its third-quarter 2026 results, published on 22 October 2026.
How Does the Deal Fit argenx’s Strategy?
argenx’s growth rests on Vyvgart, its FcRn-targeting antibody fragment. Vyvgart generated $1.7 billion in global product net sales in the third quarter of 2026. Nine-month product net sales reached $4.5 billion, according to the same results. Massey called Vyvgart “the foundation of our business”.
The argenx Unnatural Products deal follows the Forte Biosciences acquisition, which argenx completed on 27 August 2026. argenx paid $77.00 per Forte share in cash. It later said it paid approximately $2.1 billion for Forte, net of acquired cash. That deal added FB102, an anti-CD122 antibody in development for coeliac disease, vitiligo and alopecia areata. Both deals appear in the 2026 biotech M&A tracker of billion-dollar transactions.
Oral Peptides Are Already Reaching Immunology Patients
Johnson & Johnson announced FDA approval of Icotyde (icotrokinra) on 18 March 2026. Its indication is moderate-to-severe plaque psoriasis in adults and children aged 12 and over weighing at least 40 kg. Patients must also be candidates for systemic therapy or phototherapy. J&J describes it as the “first and only targeted oral peptide” blocking the IL-23 receptor. Its UK route is covered in a review of icotrokinra NHS access.
Peptides also feature in argenx’s core market. UCB announced FDA approval of zilucoplan (Zilbrysq) in October 2023. UCB calls it a “targeted peptide inhibitor of complement component 5”. Its US indication covers adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis. Vyvgart is also approved in generalised myasthenia gravis.
The market response was modest. BioPharma Dive reported that argenx shares were up nearly 3 per cent by late morning on 9 November. The same outlet quoted a note from Leerink Partners analyst Thomas Smith. The note said the acquisition “represents potential for longer-term strategic value”.
What to Watch Next
The argenx Unnatural Products deal leaves four questions open. The first is completion, which argenx guides to the end of 2026. The second is which UNP programmes, if any, enter the clinic, and when. The third is whether the Novartis, Merck and BridgeBio partnerships continue under argenx ownership. The fourth is which programmes the contingent payments of up to $595 million would cover. argenx has not yet said, and its next results update may give more detail.
